细胞名称： 人结肠腺癌细胞（STR鉴定正确）

细胞简称： SW480

细胞别称： SW-480; SW 480; SW480E；sw480细胞

货号：TCH-C348

规格： 1×10⁶cells/T25培养瓶

价格：1400元 (干冰运输需另加200元干冰费)

种属来源：人

组织来源：结肠

特征：结肠腺癌

细胞形态：上皮细胞样

生长特性：贴壁生长

培养体系：L-15+10%FBS+1%P/S

配套培养基货号：TCH-G348

传代比例：1:3-1:6，每2-3天换液一次

传代周期：48-72 h

培养条件：气相：空气，温度：37℃

冻存条件：60%基础培养基+30%FBS+10%DMSO，液氮储存

质量检测：细菌、真菌、支原体检测均为阴性

   sw480细胞源自一位51岁白人男性的原位直肠腺癌，而SW620源自同一病人一年后的淋巴结转移灶。该细胞CSAp和直肠抗原3阴性；角蛋白阳性；p53基因第273位密码子的G→A突变引起Arg→His替代，309位密码子的C→T突变导致Pro→Ser替代；细胞p53蛋白表达水平升高；癌基因c-myc、K-ras、H-ras、N-ras、myb、sis和fos的表达呈阳性；未检测到癌基因N-myc的表达；不表达Matrilysin（一种与肿瘤侵袭相关的金属蛋白酶）。有报道称该细胞表达GM-CSF。

  sw480细胞 L-15空气培养注意要点：

1. 空气培养注意要点： 

a) 人结肠腺癌细胞（SW480）使用L15空气培养基。 L-15 采用磷酸盐和游离氨基酸而非碳酸氢钠进行缓冲。这种培养基适用 于支持非 CO2 平衡环境中的细胞生长。在使用该培养体系时，须将培养 箱的二氧化碳浓度调节至“0”（维持空气培养状态），如果通入5%二氧化 碳通过培养基对细胞产生毒性。

 b) 如您没有无空气培养箱，可选择使用不透气培养瓶（密封瓶盖）培养该 细胞，并将瓶盖拧紧，每次操作时开盖短时间接触到的二氧化碳不影响该细胞正常培养。

         图示：密封瓶盖培养瓶（左）和透气瓶盖培养瓶（右）

 注意：可以选用 SW480细胞专用培养基（即用型培养基）： 已添加血清和双抗等成分，可直接用于培养SW480细胞。

参考文献：

"Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

Goodfellow M, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 77210034

Lelbovitz A, et al. Detection and analysis of a glucose 6-phosphate dehydrogenase phenotype B cell line contamination. J. Natl. Cancer Inst. 63: 635-645, 1979. PubMed: 288927

Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832

Schroy PC, et al. Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme-linked immunosorbent assay. Cancer 76: 201-209, 1995. PubMed: 8625092

Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874

Weiss J, et al. Mutation and expression of the p53 gene in malignant melanoma cell lines. Int. J. Cancer 54: 693-699, 1993. PubMed: 8514460

Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-707, 1989. PubMed: 2531845

Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498

Leibovitz A, et al. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 36: 4562-4569, 1976. PubMed: 1000501

Geiser AG, et al. Suppression of tumorigenicity in human cell hybrids derived from cell lines expressing different activated ras oncogenes. Cancer Res. 49: 1572-1577, 1989. PubMed: 2647289

Lahm H, et al. Secretion of bioactive granulocyte-macrophage colony-stimulating factor by human colorectal carcinoma cells. Cancer Res. 54: 3700-3702, 1994. PubMed: 8033086

Rodrigues NR, et al. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA 87: 7555-7559, 1990. PubMed: 1699228

Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479

Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

Zhu X, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc. Natl. Acad. Sci. USA 93: 6091-6095, 1996. PubMed: 8650224

Witty JP, et al. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res. 54: 4805-4812, 1994. PubMed: 8062282"